It remains unclear how variants like omicron could impact Covax’s ambitions going forward. In an interview in November, before the variant was identified, Seth Berkley, chief executive of Gavi, said that Covax’s “supply scarcity” could continue into the first and second fiscal quarter of 2022, but should become regular after then. On Friday, Gavi announced a new agreement with Moderna for an additional 150 million doses to become available next year, while 20 million doses originally scheduled for 2022 were to be made available before the end of the year.
The U.N.-led Covax vaccine initiative aimed to ship 2 billion doses. It won’t reach half that level.
Σχετικά άρθρα
